FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “

CZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.

FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) stock is up on Tuesday as the company is announcing a str

WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-0

Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million

FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “C

FREDERICK, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “C

Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $1.46 per share versus the Zac

Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis  Phase

Cartesian Therapeutics receives a buy rating, driven by a differentiated mRNA CAR-T approach for aut

Cartesian Therapeutics, Inc. (RNAC) was a big mover last session on higher-than-average trading volu

Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Tr

FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the

Cartesian Therapeutics, Inc. (NASDAQ: RNAC - Get Free Report) has been assigned an average rating of

Applied Therapeutics (NASDAQ: APLT - Get Free Report) and Cartesian Therapeutics (NASDAQ: RNAC - Get

Cartesian Therapeutics, Inc. (NASDAQ: RNAC - Get Free Report) has received an average rating of "Mod

FREDERICK, Md., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “

Cartesian Therapeutics, Inc. (RNAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing o

Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalim